

# EU-IPFF

EUROPEAN PULMONARY FIBROSIS FEDERATION



## ANNUAL REPORT 2021

# TABLE OF CONTENTS

<b>1</b>	<b>Foreword by Steve Jones, EU-IPFF President</b>	<b>3</b>
<b>2</b>	<b>Who we are</b>	
	2.1. Our mission	4
	2.2. The Executive Board of the EU-IPFF	5
	2.3. The Scientific Advisory Board of the EU-IPFF	5
	2.4. The EU-IPFF Secretariat: Members and Changes in 2021	7
	2.4.1. The EU-IPFF Secretariat	7
	2.4.2. Newly created position of CEO	7
	2.4.3. Report by Liam Galvin, CEO of the EU-IPFF	7
	2.5. Members and Networks	9
	2.5.1. EU-IPFF Member Organisations	9
	2.5.2. EU-IPFF Associated Members	11
	2.5.3. Professional Networks and Policy Partners	11
<b>3</b>	<b>What we do – Activities of the Federation in 2021</b>	
	3.1. New website implemented in February 2021	13
	3.2. Webinars leading up to PF Summit 2021	13
	3.3. European PF Patient Summit 2021 (23rd to 25th April 2021)	14
	3.4. Annual General Meeting 2021 (16th to 17th July 2021)	15
	3.5. EU-IPFF Awareness Campaign 2021 (September 1 <sup>st</sup> to September 30 <sup>th</sup> 2021)	15
	3.6. EU-IPFF Consultation Guide	17
	3.7. EU-IPFF Advocate Development Programme 2021/2022	17
	3.8. Partnerships and Partner Activities	17
<b>4</b>	<b>Report for Fiscal Year 2020</b>	<b>19</b>



**The COVID-19 pandemic meant 2020/21 was a difficult year for EU-IPFF. Despite this, we managed to achieve our aims and objectives. We did this by adapting our work to the challenges of the pandemic and focussing on the needs of people living with pulmonary fibrosis. We also played a key role in voicing pulmonary fibrosis patients' concerns and those of their loved ones across Europe.**

Due to the hard work of our Executive Board, Scientific Advisory Board and Secretariat, the EU-IPFF was able, with the support of our volunteers and sponsors, to:

- **successfully complete our 2021 work plan.**
- **expand our membership and international cooperation.**
- **enter into new research partnerships.**

The highlight of the year was the 1st European Pulmonary Fibrosis Patient Summit, organised by EU-IPFF. It brought together over 600 patients, carers, researchers and HCPs from around the globe for an excellent programme of talks and discussions. The Summit and the associated webinars were patient-led. They provided education, inspiration and empowerment for a community who often feel isolated and ill-informed. The Summit sessions continue to be viewed online via our website.

The successful Summit was a rallying cry from the pulmonary fibrosis (PF) community to transform and improve PF treatment and to find a cure for this devastating disease. If we are to achieve this, we will need to develop a cadre of well-trained patient advocates in all European countries. The 2021 EU-IPFF Advocate Development Programme was a first step towards this. It developed five (?) new patients and carers as leaders to campaign for changes in their home countries.

I would like to take this opportunity to welcome new EU-IPFF member organisations from Italy, Norway, Portugal and Romania. We look forward to your active participation in the work of the Federation.

We have an exciting programme of activities planned in 2022, including the 2nd European Pulmonary Fibrosis Patient Summit in November. Please take part and add your voice to our work.

With best wishes to the pulmonary fibrosis community across Europe – patients, carers, doctors and other HCPs, researchers and industry. We look forward to continuing our active cooperation with all of you in coming years.



STEVE JONES, EU-IPFF PRESIDENT

## 2.1. Our mission

The EU-IPFF is an umbrella organisation of pulmonary fibrosis patient organisations from across Europe. We are member-driven and work to raise awareness of pulmonary fibrosis in Europe among politicians, decision makers and the general public. We aim to promote a European patient voice, while recognising there are differences among countries, which may require varying approaches.

We collaborate closely with medical experts and researchers in Europe. We aim to highlight the impact of the disease on patients and their families, campaign for faster and more accurate diagnosis and encourage research and development of new treatments. We contribute to scientific articles, surveys and reports; hold summits and webinars, in collaboration with our healthcare partners; provide updates on all aspects of the disease for our members; and raise awareness of pulmonary fibrosis through our public campaigns.

We also collaborate with other organisations around the world to put pressure on healthcare authorities and educate HCPs and others about pulmonary fibrosis.

## 2.2. The Executive Board of the EU-IPFF

Our membership consists of national patient associations from across Europe, which are represented on the EU-IPFF Executive Board or within the General Assembly by PF patients and family members.



**STEVE JONES**  
**President**  
United Kingdom (UK)



**JEAN-MICHEL FOURRIER**  
**Secretary**  
France (FR)



**RALPH VAN LYSEBETH**  
**Treasurer**  
Belgium (BE)



**RADOSTINA GETOVA**  
**Board Member**  
Bulgaria (BG)



**STEFANO PAVANELLO**  
**Board Member**  
Italy (IT)



**HARRY DE WIT**  
**Board Member**  
The Netherlands (NL)



**JOHN K SOLHEIM**  
**Board Member**  
Norway (N)




**CARLOS LINES MILLÁN**  
**Emeritus President / Advisor**  
Spain (ES)

## 2.3. The Scientific Advisory Board of the EU-IPFF



**DR ELISABETTA BALESTRO**  
**Chair of Scientific Advisory Board**  
Italy (IT)



**DR FRANCESCO BONELLA**  
**Vice-Chair and Founding Chair of Scientific Advisory Board**  
Germany (DE)



**DR ALEXANDER SIMIDCHEV**  
Bulgaria (BG)



**DR ANNA-MARIA HOFFMAN-VOLD**  
Norway (N)




**PROF ANDREAS GÜNTHER**  
Germany (DE)



**DR ANNE-MARIE RUSSELL**  
United Kingdom (UK)



**PROF BRUNO CRESTANI**  
France (FR)



**DR CLAUDIA VALENZUELA**  
Spain (ES)



**DR CORMAC MCCARTHY**  
Ireland (IE)



**PROF DEMOSTHENES BOUROS**  
Greece (GR)




**DR HELEN PARFREY**  
United Kingdom (UK)



**DR HELMUT PROSCH**  
Austria (AT)



**DR IRINIA STRAMBU**  
Romania (RO)



**DR KATARZYNA LEWANDOWSKA**  
Poland (PL)



**DR KATHERINE O'REILLY**  
Ireland (IE)



**DR MARIA MOLINA**  
Spain (ES)



**DR MARLIES WIJSENBEEK**  
The Netherlands (NL)



**PROF DR MICHAEL KREUTER**  
Germany (DE)



**DR PAOLO SPAGNOLO**  
Italy (IT)



**PROF VINCENT COTTIN**  
France (FR)



**PROF WIM WUYTS**  
Belgium (BE)

## 2.4. The EU-IPFF Secretariat: Members and Changes in 2021

### 2.4.1. The EU-IPFF Secretariat

The EU-IPFF Secretariat is headed by Chief Executive (CEO) Liam Galvin and is staffed by a team of consultants from Patvocates, an organisation with broad experience in patient advocacy, health policy and patient engagement in medical research.



**LIAM GALVIN**  
**CEO of the EU-IPFF**  
Ireland (IE)



**JAN GEISSLER**  
**Patient Advocate**  
Germany (DE)



**ALBA UBIDE**  
**Project Manager**  
Spain (ES)



**STEFAN HUBER**  
**Project Manager and  
Scientific Writer/  
Editor**  
Germany (DE)



**RANDI  
KROGSGAARD**  
**Communications  
Specialist**  
Denmark (DK)

### 2.4.2. Newly created position of CEO

In January 2021, the EU-IPFF Executive Board appointed a Chief Executive Officer to drive the organisation forward and act as day-to-day head of the Secretariat. Liam Galvin, a co-founder of EU-IPFF, from Ireland, was selected by the Executive Board for this part-time, paid role. Jean-Michael Fourier was elected Secretary by the Executive Board to replace Liam Galvin.

### 2.4.3. Report by Liam Galvin, CEO of the EU-IPFF

It was a great honour to be invited, in 2021 to become EU-IPFF's first CEO. As a founding-member of the organisation, I had watched EU-IPFF develop from an informal group to a registered and recognised federation of active groups committed to being the voice of pulmonary fibrosis patients across Europe.

In 2020, the Executive Board recognised the need to professionalise the management of the organisation. The expanding activities of the EU-IPFF, could no longer be managed by volunteers alone. As a committed volunteer, among the many other volunteers who make up the EU-IPFF, I was pleased to accept the role, which allows me to devote more time to an organisation and a cause, which I passionately believe in.

I became a patient advocate after losing family members to pulmonary fibrosis but my education for the role was a bit haphazard. Given this, the launch of the EU-IPFF Advocate Development Programme is hugely exciting.

This project will see the advocates of tomorrow begin their work, well prepared and educated about today's changed advocacy environment and safeguard the federation as it expands and we grow our activities.

As CEO, I manage day-to-day activities, lead on strategic aspects of the Federation's work and seek opportunities to amplify the voice of patients suffering from pulmonary fibrosis. We have a track record of delivering projects and partnerships, and so I take this opportunity to thank our committed sponsors, our existing advocacy partners, and to welcome any potential new ones. The EU-IPFF is committed to an ethos of partnership and believes that together is stronger.


**LIAM GALVIN, CEO OF THE EU-IPFF**



## 2.5. Members and Networks

### 2.5.1. Our Member Organisations

The European Pulmonary Fibrosis Federation (EU-IPFF) brings together 21 member organisations from 15 European countries. It aims to present a unified patient voice across Europe and to support its members in helping patients and their families and to campaign for improved treatment in their own countries.





**FIMARP – Italy (IT)**



**UNIONE TRAPIANTATI POLMONE DI PADOVA – Italy (IT)**



**LONGFIBROSE PATIËNTENVERENIGING – The Netherlands (NL)**



**LHL**

Norwegian Association of Heart and Lung Patients

**LHL – NATIONAL ORGANISATION FOR HEART AND LUNG PATIENTS – Norway (N)**



**IPF POLISH SOCIETY – Poland (PL)**



**RESPIRA – Portugal (P)**



**APFPI – Romania (RO)**



**AFEFPI**

Asociación de Familiares y Enfermos de Fibrosis Pulmonar Idiopática

**ASOCIACIÓN DE FAMILIARES Y ENFERMOS DE FIBROSIS PULMONAR IDIOPÁTICA – Spain (ES)**



**ACTION FOR PULMONARY FIBROSIS – United Kingdom (UK)**




**BRITISH LUNG FOUNDATION – United Kingdom (UK)**



**PULMONARY FIBROSIS TRUST – United Kingdom (UK)**

## 2.5.2. Our Associated Members



## 2.5.3. Professional Networks and Policy Partners

The EU-IPFF enters into partnerships with professional networks and policy organisations to provide a voice for our patient community and to support joint efforts in awareness, education, policy and research. Our partners are European and global.






**INTERSTITIAL LUNG DISEASE, ILD  
NETWORK – United Kingdom**



**MEP Lung Health Group**

**MEP LUNG HEALTH GROUP  
– Switzerland**

**CENTRAL EUROPEAN  
IPF ALL PATIENTS NETWORK**



**CENTRAL EUROPEAN IPF NETWORK  
– Central Europe**



European  
Reference  
Network

Respiratory Diseases  
(ERN-LUNG)


**ERN-LUNG – Germany**

This section gives an overview of the activities carried out by the EU-IPFF in 2021.

### 3.1. New website implemented in February 2021

In February 2021, the EU-IPFF launched an updated and new website. It has been completely restructured allowing for easy navigation, faster loading times and the best possible user experience. It includes a news section and an embedded newsletter that comes out 3-4 times a year.

The new website is based on TYPO3, a user-friendly, secure and open-source content management system.




### 3.2. Webinars leading up to PF Summit 2021

In the lead up to the 2021 PF Summit, the EU-IPFF hosted a series webinars, moderated by EU-IPFF President Steve Jones. Each of the webinars was attended by over 100 people and recordings were made available for others to view. Speakers included leading experts and researchers in pulmonary fibrosis: Prof. Gisli Jenkins, Prof. Michael Kreuter, Dr. Raphaël Borie, Dr. Coline van Moorsel and Dr. Marlies Wijsenbeek.

#### Webinars:

- COVID-19 and Pulmonary Fibrosis
- Progressive ILD and comorbidities
- Genetics in ILD – Genotypes, Phenotypes and the Future
- Optimising Quality of Life in Patients with pulmonary fibrosis



You can find the recordings of the webinars [here](#).

The webinars were kindly sponsored by Boehringer Ingelheim, Galápagos, Roche, BMS, Avalyn Pharma and Chiesi.

### 3.3. 1<sup>st</sup> European Pulmonary Fibrosis Patients' Summit 2021 (23rd – 25th April 2021)

The 1st European Pulmonary Fibrosis Patients' Summit took place virtually over three days. It brought together over 600 patients, carers, researchers and HCPs from around the globe for an excellent programme of talks and discussions. The event was designed jointly with patients and 61% of participants were either patients or caregivers. The 15 sessions included presentations by 52 leading European researchers, clinicians, healthcare professionals, policy makers and industry representatives. Patients were also actively involved as presenters in the sessions.

The Summit covered a wide range of topics in research, person-centred care and advocacy, and included two industry symposia by Boehringer Ingelheim and Galápagos. All Summit sessions were streamed live via the virtual event platform Swapcard. During the sessions, the attendees were able to ask questions and add comments in the live discussion panel.

#### Sessions of the 2021 European PF Patient Summit

1. Opening Session
2. Mechanism of action of fibrosis and new insights on antifibrotic drugs
3. Self-management of interstitial lung disease (ILD)
4. Supporting newly diagnosed patients
5. Breaking barriers: How to optimise communication between physicians, patients and loved ones
6. Industry Symposium: Improving the path to diagnosis in Europe: the doctor, patient and caregiver's perspectives
7. Non-pharmacological management of PF and evaluation for lung transplant
8. Involvement of rare disease patient representatives in medical congresses
9. Clinical trials for PF and an overview of potential therapies moving forward
10. Role of interdisciplinary team in hospice and end of life
11. Multidisciplinary and/or interdisciplinary approaches to ILD care
12. Pulmonary rehabilitation for PF patients
13. What patients want to know about research and how they can be involved?
14. The 2030 EU Agenda on rare diseases
15. Closing Session.

You can find the in-depth report for the 2021 European PF Patient Summit [here](#). The first European PF Patient Summit was kindly sponsored by Boehringer Ingelheim, Galápagos, Roche, BMS, Avalyn Pharma and Chiesi.



### 3.4. Annual General Meeting 2021 (16th – 17th July 2021)

The 2021 Annual General Meeting took place on-line. All member organisations participated. Respira (Portugal) and NHL (Norway) became new full members of the organisation, APFPI (Romania) became a new provisional full member, and Respiriamo Insieme (Italy) became a new provisional associate member of the EU-IPFF.



The Executive Board welcomed John Solheim, Harry de Wit and Radostina Getova as newly elected members, and voted unanimously for Jean-Michel Fourier as secretary for the next two years. Klaus Geissler was thanked for his commitment and will continue to be consulted by the Executive Board.

**The newly elected Chair of the EU-IPFF Scientific Advisory Board is Dr Elisabetta Balestro, University Hospital of Padova, Italy,**

I would like to serve the Federation as a trusted clinician and scientist for improving disease awareness across Europe and for developing projects aimed to improve the quality of life of patients with progressive diseases. Knowledge and enthusiasm are the main drivers of people who belong to the Federation which provides us with a unique opportunity, as clinicians, to actively collaborate with patients and their carers.

**DR. ELISABETTA BALESTRO, CHAIR OF THE SCIENTIFIC ADVISORY BOARD**

### 3.5. EU-IPFF Awareness Campaign 2021 (September 1st – September 30th 2021)



Newly established under the motto **#BreathlingLife**, the 2021 campaign aimed to raise awareness of pulmonary fibrosis (PF), using facts, figures and stories of patients and carers during the month of September. The campaign focussed specifically on the problems of people living with idiopathic pulmonary fibrosis (IPF) during IPF Awareness Week from September 18th–30th.

The campaign covered key disease-related topics such as the disease area itself, diagnosis, treatment, research, and quality of life, culminating in the topic awareness and a call to action.

With the help of a graphic designer, the campaign team created a range of digital and non-digital materials translated in 10 languages, including booklets, flyers, customisable postcards, stickers as well as enamel pins. A unique visual was specifically developed for the campaign, which aimed to demonstrate the vulnerability of the lungs and, at the same time, convey a message of hope. The visual, an abstract representation of the human lungs, visualises the scarring of the lung tissue, with natural elements such as flowers and leaves symbolising the concepts of “life” and “breathing”.



The 2021 campaign also encouraged patients to tell their personal story by sharing a video about their experience of living with PF, emphasising their individual moments of light heartedness, ease and happiness. They used the same campaign hashtags **#BreathingLife** or **#PFMonth**. The campaign team also used the social media platforms Twitter, Facebook, LinkedIn and Instagram to promote the **#BreathingLife Campaign**. They produced tailored social media posts and visuals, and a teaser video targeted at patients, carers, nurses and other stakeholders, as well as the general public between September 1st and September 30th 2021. All campaign materials, including social media posts and digital materials, were also made available on the EU-IPFF Awareness website.

To further raise awareness of the campaign’s cause and support ERN-LUNG (the European Reference Network on Respiratory Diseases), an artistic version of the human lungs in an oak frame and hand-cut by Marie-Christine Hollerith, a papercut artist and the creative mind behind the **#BreathingLife campaign**, was sold by auction during IPF Awareness Week.

In addition, Samantha Nier, a member of the campaign team and certified yoga instructor, offered daily yoga sessions tailored to the needs and capabilities of IPF patients throughout IPF Awareness Week.

The 2021 Awareness Campaign was kindly sponsored by Boehringer Ingelheim and Roche Group.

You can find the in-depth report for the 2021 Awareness Campaign [here](#).



### 3.6. EU-IPFF Consultation Guide

The Federation is currently working on an up-to-date and concise version of its consultation guide that will cover all forms of progressive pulmonary fibrosis and will come out in two versions: one aimed at patients and the other at healthcare professionals. The Roche guide will be available for download in 10 languages.

The EU-IPFF Consultation Guide is kindly sponsored by Boehringer Ingelheim, Roche and Vicore Pharma.

### 3.7. EU-IPFF Advocate Development Programme 2021/2022

To better represent the needs of PF patients, advocate effectively on their behalf and to increase impact of PF patient advocacy, five patient advocates in field of PF from the Netherlands, UK and Greece took part in an Advocate Development Programme (ADP) from June 2021 till April 2022. The programme was designed by the EU-IPFF and the think-tank Patvocates. It was made up of regular webinars and interactive training sessions, aims to increase the members' capacity as leading patient advocates in IPF/ PF and related disorders and will enable the participants to become an influential expert patient advocate.

The EU-IPFF ADP 2021/2022 was kindly sponsored by Boehringer Ingelheim, Galápagos and Roche.

### 3.8. Partnerships and Partner Activities

The EU-IPFF is an experienced public and patient involvement (PPI) partner. Over the years, we have supported and endorsed several research funding applications, been active members of consortiums and contributed our expertise and the views of patients to various academic research papers and publications.

In 2021, an article based on a survey by EU-IPFF was published in the journal *Frontiers in Medicine* on 'Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey'. **The article was co-authored by Steve Jones (EU-IPFF President) and members of the SAB, and can be accessed [here](#).**<sup>1</sup>

#### Survey to explore patients' and carers' views on the treatment of IPF

The EU-IPFF has joined with York Health Economics Consortium (YHEC, University of York) to run a survey to study patient and carer views on the treatments for IPF. The aim of the survey is to better understand what is important to people living with IPF and improve future discussions between patients and doctors on treatments.

1 van der Sar IG, Jones S, Clarke DL, Bonella F, Fourrier JM, Lewandowska K, Bermudo G, Simidchiev A, Strambu IR, Wijsenbeek MS, Parfrey H. Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. *Front Med (Lausanne)*. 2021 Aug 4;8:711194. doi: 10.3389/fmed.2021.711194. PMID: 34422866; PMCID: PMC8371687.

### **CIG-16125**

The EU-IPFF and its Irish group ILFA supported this successful application under the European COST Innovators Grant programme. Led by RSCI University of Medicine and Health Sciences in Ireland, it aims to develop an open access repository of pluripotent stem cells from children and adults with interstitial lung disease.

### **COSCO- IPF**

The EU-IPFF is a patient organisation partner for this multi-partnership academic research project led by the University Hospital Leuven in Belgium which aims to co-design with patients a core patient reported and clinical outcome set for IPF Patients. Successfully funded in 2021, the project will begin in 2022.

### **European Lung Health Group**

In late 2021, the EU-IPFF came together with the ERS and the other largest European patient organisations to form the European Lung Health Group. As a collective initiative driven by European level patient groups and healthcare professionals, it is an informal grouping of 179 member associations from 34 European Countries. Its mission is to bring together know-how to support its organisations in empowering patients with lung disease, improving quality of life, optimising multidisciplinary care, early diagnosis and research. As a group, the ELHG will be collectively promoting the need for better respiratory health care, increased patient involvement and improved prevention at European and global levels.

### **RARE-ILD**


The EU-IPFF is a patient organisation partner for this successfully funded project led by the University Hospital of Giessen and Marburg, Germany. A large consortium of partners from across Europe, it aims to develop novel, primarily non-invasive diagnostic algorithms and biomarkers for rare ILDs, including pulmonary fibrosis. Successfully funded in 2020, background work has continued during the Covid-19 pandemic with the full project starting in 2022.

During Fiscal year 2020 (June 2019 to May 2020), the EU-IPFF received a total of 673.352,30 € as operating income ([see here](#) the audited accounting report as provided to the Belgian authorities).

The following graph shows (i) the distribution of the overall funding received by the Federation by type of funding and (ii) an overview of the percentage provided by each of the pharmaceutical companies as sponsorships (68% of the overall income). The pharmaceutical company Boehringer Ingelheim provided a relatively high proportion of EU-IPFF funds – 31.1% of the overall income. See graphic and table below with further details.

From the pharmaceutical income, 71% ( 323,500.00 € ) was destined for the EU-IPFF projects including the planning of the 1st PF Summit. The other 29% of the sponsorship income( 131,083.30 € ) was used to run the EU-IPFF Secretariat during the aforementioned fiscal year. The Secretariat costs, cover the day to day activities, face to face Board Meetings and the General Assembly, software costs, etc.

The EU-IPFF concluded the 2020 Fiscal Year with a final balance of + 18,259.28 €.



Name of company/ funder	Amount of income	% of overall EU-IPFF's income
Boehringer Ingelheim	€ 209,583.30	31.10%
F. Hoffmann - La Roche Ltd	€ 115,000.00	17.10%
Galapagos NV	€ 100,000.00	14.90%
Respivant Sciences	€ 10,000.00	1.50%
Action Pulmonary Fibrosis	€ 5,000.00	0.70%
Avalyn Pharma	€ 5,000.00	0.70%
Promedior	€ 5,000.00	0.70%
Vicore Pharma Holding	€ 5,000.00	0.70%

The EU-IPFF is registered in Belgium as a International Not for Profit Organisation. Fully compliant with Belgium law and financial regulations it is committed to transparency in its financial matters. Its audited accounts are prepared by FIDIAZ (previously known as Finivo) on a annual basis and are available publicly in Belgium, can be accessed on our website and are registered with the Europa Transparency Register and can be seen in the attached Annex.

The full accounts for 2020 linked to this annual report are for the income and expenditure for the financial year which ran from July 2019 to July 2020. From January 2023 the financial year of the EU-IPFF will be changed legally to run from January to December.

The EU-IPFF is a membership based organisation and its executive board operates on a voluntary basis.

## Internal balance

	05/2020	05/2019	05/2018	05/2017
<b>Assets</b>				
<b>Current assets</b>	<b>255,200.72</b>	<b>333,405.51</b>	<b>396,644.11</b>	<b>263,565.42</b>
<b>VII. Receivables of less than one year</b>	<b>85,518.94</b>	<b>99,687.91</b>	<b>278,500.00</b>	<b>236,500.00</b>
<b>A. Commercial receivables</b>	<b>83,796.60</b>	<b>97,492.22</b>	<b>278,500.00</b>	<b>236,500.00</b>
400000 Commercial Receivables - Invoicing	83,796.60	77,577.89	268,500.00	0.00
400400 Commercial Rec. - Invoices to be issued	0.00	0.00	0.00	236,500.00
406000 Prepayments	0.00	19,914.33	10,000.00	0.00
<b>B. Other receivables</b>	<b>1,722.34</b>	<b>2,195.69</b>	<b>0.00</b>	<b>0.00</b>
416020 R/C Liam	1,722.34	2,195.69	0.00	0.00
<b>IX. Liquidities</b>	<b>169,681.78</b>	<b>233,717.60</b>	<b>118,144.11</b>	<b>27,065.42</b>
552000 Ing	169,681.78	233,717.60	118,144.11	27,065.42
<b>TOTAL ASSETS</b>	<b>255,200.72</b>	<b>333,405.51</b>	<b>396,644.11</b>	<b>263,565.42</b>

	05/2020	05/2019	05/2018	05/2017
<b>Liabilitie</b>				
<b>Equity</b>	<b>168,961.49</b>	<b>150,702.21</b>	<b>306,526.49</b>	<b>167,598.96</b>
<b>V. Balance carried forward</b>	<b>168,961.49</b>	<b>150,702.21</b>	<b>306,526.49</b>	<b>167,598.96</b>
140000 Profits carried forward	168,961.49	150,702.21	306,526.49	167,598.96
Current period results	0.00	0.00	0.00	0.00
<b>Debts</b>	<b>86,239.23</b>	<b>182,703.30</b>	<b>90,117.62</b>	<b>95,966.46</b>
<b>IX. Debts of up to one year</b>	<b>86,239.23</b>	<b>182,703.30</b>	<b>55,117.62</b>	<b>95,966.46</b>
<b>C. Commercial debts</b>	<b>92,481.36</b>	<b>182,393.30</b>	<b>55,017.62</b>	<b>95,966.46</b>
440000 Suppliers	73,446.60	161,746.44	24,214.63	95,966.46
440100 VISA payable	-879.57	732.53	0.00	0.00
444000 Invoices to be received	19,914.33	19,914.33	30,802.99	0.00
<b>D. Advance payments received</b>	<b>0.00</b>	<b>0.00</b>	<b>100.00</b>	<b>0.00</b>
460000 Advance payments on orders.	0.00	0.00	100.00	0.00
<b>F. Other debts</b>	<b>-6,242.13</b>	<b>310.00</b>	<b>0.00</b>	<b>0.00</b>
480100 Expense notes to be paid	-6,242.13	310.00	0.00	0.00
<b>X. Accruals and deferred income</b>	<b>0.00</b>	<b>0.00</b>	<b>35,000.00</b>	<b>0.00</b>
493000 Deferred income	0.00	0.00	35,000.00	0.00
<b>TOTAL LIABILITIES</b>	<b>255,200.72</b>	<b>333,405.51</b>	<b>396,644.11</b>	<b>263,565.42</b>

## Internal income statement

	05/2020	05/2019	05/2018	05/2017
<b>I. Operating Income</b>	<b>673,352.86</b>	<b>490,177.89</b>	<b>624,500.00</b>	<b>940,800.00</b>
<b>A. Turnover</b>	<b>673,352.86</b>	<b>490,177.89</b>	<b>624,500.00</b>	<b>940,800.00</b>
700000 Sales V.A.T. 0%	147,545.00	490,177.89	624,500.00	940,800.00
700010 Membership fees	1,900.00	0.00	0.00	0.00
700310 Sponsorship	454,583.30	0.00	0.00	0.00
700320 Sales	53,809.56	0.00	0.00	0.00
700700 Export sales	15,515.00	0.00	0.00	0.00
<b>II. Operating costs</b>	<b>-654,608.83</b>	<b>-645,347.15</b>	<b>-485,263.16</b>	<b>-773,174.28</b>
<b>A. Commercial goods, raw materials and consumables</b>	<b>-575,550.31</b>	<b>-572,742.38</b>	<b>-475,203.36</b>	<b>-772,781.52</b>
603000 Subcontracting	-546,940.41	-572,742.38	-473,359.95	-769,855.20
604000 Purchases of commercial goods	0.00	0.00	-1,843.41	-2,926.32
606000 Chargeable costs	-28,609.90	0.00	0.00	0.00
<b>B. Services and various goods</b>	<b>-79,058.52</b>	<b>-72,604.77</b>	<b>-10,059.80</b>	<b>-392.76</b>
611000 Office supplies and printed matter	-889.40	-38.20	0.00	0.00
611010 Computer supplies	-432.00	0.00	0.00	0.00
611020 Web site	-6,486.25	-5,576.03	0.00	0.00
611100 Books, brochures and documentation	0.00	-31.00	0.00	0.00
612000 Publicity and announcements	-29.58	0.00	0.00	0.00
612050 Legal publications	-257.73	-420.23	-219.01	0.00
612100 Participation in fairs and exhibitions	0.00	-300.00	0.00	0.00
612400 Seminars and training	-1,165.00	0.00	0.00	0.00
612800 Gifts and liberalities	-100.00	-1,765.78	0.00	0.00
612850 Sponsorship	0.00	-9,966.30	-5,857.13	0.00
612900 Limited reception costs	-1,251.68	-79.50	0.00	0.00
612910 Limited restaurant costs	-4,741.95	-602.30	0.00	0.00
612950 Unlimited reception costs	-16,844.53	-4,143.90	0.00	-120.00
613100 Travel expenses abroad	-26,070.17	-5,323.48	-1,756.05	-272.76
613200 Parking	-585.31	-75.95	0.00	0.00
613300 Taxi	-126.10	-65.00	0.00	0.00
615200 Accountants' fees	-4,375.36	-3,195.92	-2,227.61	0.00
615600 Miscellaneous fees	-6,859.90	-8,784.53	0.00	0.00
615700 Lawyers' fees	-8,843.56	-32,236.65	0.00	0.00
<b>Operating profit/loss</b>	<b>18,744.03</b>	<b>-155,169.26</b>	<b>139,236.84</b>	<b>167,625.72</b>

	05/2020	05/2019	05/2018	05/2017
<b>IV. Financial income</b>	<b>0.01</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>B. Income from current assets</b>	<b>0.01</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
751000 Income from current assets	0.01	0.00	0.00	0.00
<b>V. Financial costs</b>	<b>-484.76</b>	<b>-655.02</b>	<b>-309.31</b>	<b>-26.76</b>
<b>C. Other financial costs</b>	<b>-484.76</b>	<b>-655.02</b>	<b>-309.31</b>	<b>-26.76</b>
654000 Foreign Exchange results	0.00	0.00	-155.36	0.00
656000 Financial differences (-)	-0.01	0.00	0.00	0.00
656100 Bank and giro costs	-484.75	-655.02	-153.95	-26.76
<b>Profit/loss from ordinary activities</b>	<b>18,259.28</b>	<b>-155,824.28</b>	<b>138,927.53</b>	<b>167,598.96</b>
<b>Profit/loss of the financial year before tax</b>	<b>18,259.28</b>	<b>-155,824.28</b>	<b>138,927.53</b>	<b>167,598.96</b>
<b>PROFIT/LOSS OF THE FINANCIAL YEAR</b>	<b>18,259.28</b>	<b>-155,824.28</b>	<b>138,927.53</b>	<b>167,598.96</b>



## Processing results

	05/2020	05/2019	05/2018	05/2017
<b>A. Profit/loss to be distributed</b>	<b>168,961.49</b>	<b>150,702.21</b>	<b>306,526.49</b>	<b>167,598.96</b>
1. Profit/loss to be allocated for the financial year	18,259.28	-155,824.28	138,927.53	167,598.96
2. Result transfer from the previous financial year	150,702.21	306,526.49	167,598.96	0.00
790000 Profit transfer from the previous financial year	150,702.21	306,526.49	167,598.96	0.00
<b>B. Deduction from equity</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
1. Withdrawal of capital and issue premiums	0.00	0.00	0.00	0.00
2. Withdrawal from reserves	0.00	0.00	0.00	0.00
<b>C. Addition to equity</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
1. Addition to the capital and the issue premiums	0.00	0.00	0.00	0.00
2. Addition to the legal reserve	0.00	0.00	0.00	0.00
3. Addition to other reserves	0.00	0.00	0.00	0.00
<b>D. Result to be transferred</b>	<b>-168,961.49</b>	<b>-150,702.21</b>	<b>-306,526.49</b>	<b>-167,598.96</b>
1. Profit to be transferred	-168,961.49	-150,702.21	-306,526.49	-167,598.96
693000 Profit to be transferred	-168,961.49	-150,702.21	-306,526.49	-167,598.96
2. Loss to be transferred	0.00	0.00	0.00	0.00
<b>E. Intervention of partners in the loss</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
<b>F. Profit to be distributed</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
1. Capital return	0.00	0.00	0.00	0.00
2. Directors or managers	0.00	0.00	0.00	0.00
3. Other beneficiaries	0.00	0.00	0.00	0.00
<b>RESULT TO BE PROCESSED FOR THE FINANCIAL YEAR</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>

**EU-IPFF**  
EUROPEAN PULMONARY FIBROSIS FEDERATION

